|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3 The association between atrial fibrillation and the study outcomes in the sensitivity analyses** | | | | | | | | |
| **The study outcomes** | **adjusted hazard ratio** | | **95% confidence interval** | | | | **P** | |
| **All-cause mortality at one year** |  |  | | |  | | |  |
| **Model 1** | **2.416** | **1.204** | | | **-4.845** | | | **0.013** |
| **Model 2** | **2.141** | **1.047** | | | **-4.377** | | | **0.037** |
| **Model 3** | **2.533** | **1.304** | | | **-4.917** | | | **0.006** |
| **Model 4** | **2.080** | **0.950** | | | **-4.555** | | | **0.067** |
| **Model 5** | **2.158** | **1.012** | | | **-4.605** | | | **0.047** |
| **Model 6** | **2.209** | **1.036** | | | **-4.710** | | | **0.040** |
| **Cardiac-related mortality** |  |  | | |  | | |  |
| **Model 1** | **2.276** | **0.853** | | | **-6.075** | | | **0.101** |
| **Model 2** | **2.176** | **0.801** | | | **-5.913** | | | **0.127** |
| **Model 3** | **2.483** | **0.979** | | | **-6.297** | | | **0.055** |
| **Model 4** | **2.022** | **0.708** | | | **-5.778** | | | **0.189** |
| **Model 5** | **2.169** | **0.789** | | | **-5.963** | | | **0.133** |
| **Model 6** | **2.169** | **0.792** | | | **-5.938** | | | **0.132** |
| **Major adverse cardiac events at one year** |  |  | | |  | | |  |
| **Model 1** | **2.303** | **1.032** | | | **-5.140** | | | **0.042** |
| **Model 2** | **1.869** | **0.795** | | | **-4.393** | | | **0.151** |
| **Model 3** | **2.408** | **1.117** | | | **-5.191** | | | **0.025** |
| **Model 4** | **1.682** | **0.699** | | | **-4.048** | | | **0.246** |
| **Model 5** | **1.780** | **0.760** | | | **-4.172** | | | **0.184** |
| **Model 6** | **1.757** | **0.753** | | | **-4.099** | | | **0.192** |
| **Model 1 adjusted for creatinine in addition to age, gender, heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** | | | | | | | | |
| **Model 2 adjusted for creatinine clearance in addition to heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** | | | | | | | | |
| **Model 3 adjusted for estimated glomerular filtration rate in addition to heart rate, the presence of acute limb ischemia, Rutherford classification stages, neutrophil-to-lymphocyte ratio.** | | | | | | | | |
| **Mode 4 additionally adjusted for body mass index on the top of the model 1.** | | | | | |  | | |
| **Model 5 additionally adjusted for body mass index on the top of model 2.** | | | |  | |  | | |
| **Model 6 additionally adjusted for body mass index on the top of model 3.** | | | |  | |  | | |